Drugmaker Novartis climbs 4.4% after guidance rise on sales of blockbuster drugs
Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.
